Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Human Metabolome Technologies EV-to-EBITDA?
Human Metabolome TechnologiesTSE:6090 -0.16%62 EV-to-EBITDA is 5.01 as of Sep. 04, 2026, which is 40% below its 10-year median of 8.30. GuruFocus rates TSE:6090 with a GF Score™ of 62/100 and a GF Value™ of 円694.71 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 122 Medical Diagnostics & Research companies, Human Metabolome Technologies ranks better than 86.89% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Human Metabolome Technologies's enterprise value is 円1,972 Mil.
Human Metabolome Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円394 Mil. Therefore, Human Metabolome Technologies's EV-to-EBITDA for today is 5.01.
The historical rank and industry rank for Human Metabolome Technologies's EV-to-EBITDA or its related term are showing as below:
TSE:6090'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -286.28 Med: 8.3 Max: 190.24
Current: 5.01
During the past 13 years, the highest EV-to-EBITDA of Human Metabolome Technologies was 190.24. The lowest was -286.28. And the median was 8.30.
TSE:6090's EV-to-EBITDA is ranked better than 86.89% of 122
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.23
vs TSE:6090: 5.01
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Human Metabolome Technologies (TSE:6090) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Human Metabolome Technologies's PE Ratio (TTM) for today is calculated as:
Human Metabolome Technologies's share price for today is 円616.00.
Human Metabolome Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円35.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6090 vs TMO, DHR, NTRA: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Human Metabolome Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's EV-to-EBITDA falls into.
Human Metabolome Technologies's current Enterprise Value is 円1,972 Mil.
Human Metabolome Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円394 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies (TSE:6090) has a EV-to-EBITDA of 5.01 as of Sep. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Human Metabolome Technologies. This is 40% below median its historical median of 8.30. According to the industry distribution chart, Human Metabolome Technologies ranks #16 out of 122 companies in the Medical Diagnostics & Research industry, placing it in the top 13.1%.
Is Human Metabolome Technologies' EV-to-EBITDA too high?
Human Metabolome Technologies' current EV-to-EBITDA of 5.01 is 40% below median its 10-year median of 8.30. The Medical Diagnostics & Research industry median EV-to-EBITDA is 16.23. Human Metabolome Technologies' value of 5.01 is 69.1% below this industry median. Based on the distribution chart, Human Metabolome Technologies ranks #16 out of 122 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Human Metabolome Technologies has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #16 out of 122 companies for EV-to-EBITDA. This places Human Metabolome Technologies in the top 13% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 16.23. Human Metabolome Technologies' value of 5.01 is 69.1% below this benchmark. While the company's 10-year median is 8.30 vs. the industry median of 16.23, Human Metabolome Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 16.23, based on 122 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Human Metabolome Technologies's current EV-to-EBITDA of 5.01 is 69.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Human Metabolome Technologies. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 16.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Human Metabolome Technologies's current EV-to-EBITDA is 5.01, which is 40% below median its own 10-year median of 8.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Undervalued. The stock's GF Value™ is 円694.71, compared to a current price of 円616.00 — trading 11.3% below its estimated fair value. The current EV-to-EBITDA is 5.01, which is 40% below median its 10-year median of 8.30 and 69.1% below the Medical Diagnostics & Research industry median of 16.23. Human Metabolome Technologies' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current EV-to-EBITDA is 5.01 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be undervalued.
The current stock price of 円616.00 is trading 11.3% below its estimated GF Value™ of 円694.71.
GuruFocus considers Human Metabolome Technologies to be Modestly Undervalued.
Key valuation signals for TSE:6090:
EV-to-EBITDA: 5.01 (40% below median its 10-year median of 8.30)
GF Value™: 円694.71 vs. price of 円616.00 (11.3% below fair value)
Industry Position: 69.1% below the Medical Diagnostics & Research median (#16 of 122)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
